RxDoctor Payments Data

Kalan Kelch

Acute Care · Goodyear, AZNPI 1659764124

Payments from drug & device makers

$1,980in general payments, 2019–2025

Across 104 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$412
  • Collegium Pharmaceutical, Inc.$240
  • Valinor Pharma, LLC$199
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$139
  • Avanos Medical$125
  • AbbVie$120
  • plus $745 from 16 others

What the payments were for

  • Food & beverage$1,980100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,980 in reported general payments places this provider in the 75th percentile of 482 acute care providers in Arizona.

See all acute care providers in Arizona

Medicare billing

Part B allowed, 2024
$32,595
Medicare patients
218
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$33,169
MovantikNaloxegol Oxalate29$30,065
OzempicSemaglutide24$28,330
Xtampza ErOxycodone Myristate36$16,282
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen367$14,479
BelbucaBuprenorphine Hcl18$12,511
Buprenorphine43$9,895
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen354$7,877
Gabapentin273$5,997
Pregabalin138$4,217
Oxycodone Hcl173$3,700
Morphine Sulfate ErMorphine Sulfate140$3,078
Methocarbamol94$2,882
Tizanidine Hcl104$2,712
Lidocaine31$2,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$240$28,79354 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$14$10,57379 claims
AbbVieSynthroid$120$75215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 482 acute care providers in Arizona.

Other acute care in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →